Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX:PYNKF) announced that Covenant Health Fort Sanders Regional is the first hospital in Tennessee to implement its optical coherence technology (OCT) technology, S-Series OCT, for real-time tissue margin visualization in the operating room.
According to Perimeter, traditional technologies such as X-ray, ultrasound, and MRI lack the resolution to detect disease at the cellular level. As a result, surgeons often wait up to ten days for pathology results to confirm clean margins or identify positive margins, which may require patients to undergo additional procedures.
“OCT technology enhances the level of care I am able to provide and has become a valuable tool in the operating room,” Dr. Ana Wilson, a surgical oncologist with Covenant Health Fort Sanders Regional, said in a statement. “It allows me to make patient-specific surgical decisions in real-time and potentially reduce the likelihood of my patients returning for a second surgery.”
Sara Brien, CFO of Perimeter commented, “Being the first in Tennessee is another milestone in our continued expansion into new geographies nationwide. Bringing our Perimeter S-Series OCT to Covenant Health Fort Sanders Regional also advances an important company goal of broadening access to our innovative technologies for margin visualization, in real-time, in the OR, to potentially improve outcomes and reduce healthcare costs.”
The S-Series OCT generates cross-sectional 3D images of tissue microstructures with ten times the resolution of ultrasound and X-ray and 100 times the resolution of MRI. Capable of imaging down to 2 mm in ducts, vessels, and glands, the technology provides surgeons with real-time clarity on margins, equipping them with critical insights to make informed surgical decisions with greater confidence.
As a breast cancer survivor, Suzanne Foster, chairperson of Perimeter’s BOD, has a personal connection to the company’s mission to transform cancer surgery, understanding the need for all patients to have access to advanced technology with the hope of improving surgical outcomes. “Perimeter is working tirelessly to help surgeons provide the best possible care for their patients,” she said.
In November 2024, Perimeter reported positive topline results from the pivotal study designed to support its planned FDA PMA application to market its next-generation, breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI for use during breast-conserving surgeries in the United States. The company has indicated that it plans to submit its FDA PMA for the Perimeter B-Series in early 2025.
